SJS Investment Consulting’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

SJS Investment Consulting’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$24.4K	Hold	154	–	–	﹤0.01%	723
2026 Q1	$19.7K	Hold	154	–	–	﹤0.01%	675
2025 Q4	$18.8K	Buy	+154	New	+$17.7K	﹤0.01%	644
2025 Q2	–	Sell	-22	Closed	-$1.78K	–	1677
2025 Q1	$1.78K	Buy	+22	New	+$1.97K	﹤0.01%	776

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SJS Investment Consulting's XBI Position: Q2 2026 in Review

SJS Investment Consulting held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q2 2026 at 154 shares worth $24.4K. The position accounts for ﹤0.01% of the portfolio, ranked #723.

SJS Investment Consulting first reported a position in XBI in Q1 2025 and has held it in 4 quarters since. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

SJS Investment Consulting held 154 shares of State Street SPDR S&P Biotech ETF worth $24.4K as of Q2 2026.
SJS Investment Consulting left its State Street SPDR S&P Biotech ETF share count unchanged in Q2 2026.
State Street SPDR S&P Biotech ETF made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #723 holding.
SJS Investment Consulting first reported a position in State Street SPDR S&P Biotech ETF in Q1 2025 and has held it in 4 quarters since.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.